BTK and diffuse large B-cell lymphoma: While multiple targets are currently evaluated in clinical trials for treatment of DLBCL such as NF-κB and PI3K/AKT/mTORC pathways, Bruton’s tyrosine kinase (BTK), Spleen tyrosine kinase (SYK), enhancer of zeste hormone 2 (EZH2), phosphoinositide-3-kinase (PI3K), Janus Kinases (JAK), and anti-apoptotic proteins (e.g. BCL2, MCL1) (27, 28), we will mainly focus on immune-based therapeutic interventions.